Company Description
Emmaus Life Sciences, Inc., a commercial-stage biopharmaceutical company, discovers, develops, markets, and sells treatments and therapies primarily for rare and orphan diseases in the United States and internationally.
The company's lead candidate is Endari, an L-glutamine oral powder to reduce the acute complications of sickle cell disease in adult and pediatric patients five years of age and older.
It has a collaboration agreement with Kainos Medicine, Inc. for the preclinical development of Kainos' patented IRAK4 inhibitor (KM10544) as an anti-cancer drug.
The company was formerly known as Emmaus Holdings, Inc. and changed its name to Emmaus Life Sciences, Inc. in September 2011.
The company was founded in 2000 and is headquartered in Torrance, California.
| Country | United States |
| Founded | 2000 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 54 |
| CEO | Willis C. Lee M.S. |
Contact Details
Address: 21250 Hawthorne Boulevard, Suite 800 Torrance, California 90503 United States | |
| Phone | 310-214-0065 |
| Website | emmausmedical.com |
Stock Details
| Ticker Symbol | EMMA |
| Exchange | OTCMKTS |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0000822370 |
| CUSIP Number | 29137T101 |
| ISIN Number | US29137T1016 |
| Employer ID | 87-0419387 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Willis C. Lee M.S. | Co-President, Chief Operating Officer and Chairman of the Board |
| Yasushi Nagasaki CPA, CPA | Chief Financial Officer |
| George Sekulich | Co-President, Chief Commercial Officer and Director |
| Dale E. Short J.D. | Legal Consultant and Corporate Secretary |
| Dr. Charles W. Stark Pharm.D, Pharm.D. | Senior Vice President of Medical Affairs, Clinical, Regulatory |
| Kurt H. Kruger M.B.A., M.S. | Consultant |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 1, 2024 | NT 10-K | Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 |
| Feb 26, 2024 | 8-K | Current Report |
| Dec 22, 2023 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Dec 20, 2023 | 8-K | Current Report |
| Nov 14, 2023 | 8-K | Current Report |
| Nov 14, 2023 | 10-Q | Quarterly Report |
| Oct 4, 2023 | 8-K | Current Report |
| Aug 23, 2023 | 8-K | Current Report |
| Aug 14, 2023 | 8-K | Current Report |
| Aug 14, 2023 | 10-Q | Quarterly Report |